You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 142 No. 3, March 2006 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Observation
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (25)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Behavioral Neurology
 •Dermatology
 •Dermatologic Disorders
 •Dermatologic Disorders, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Successful Treatment of Delusions of Parasitosis With Olanzapine

William J. Meehan, MD, PhD; Sonia Badreshia, MD; Christine L. Mackley, MD

Arch Dermatol. 2006;142:352-355.

Background  Delusional parasitosis is a rare disorder in which patients have a fixed, false belief of being infested with parasites. It is often accompanied by a refusal to seek psychiatric care. Delusions of parasitosis is classically treated with typical antipsychotic agents, the traditional dermatologic choice being pimozide. However, pimozide's adverse effect profile and the need for frequent electrocardiographic monitoring make such treatment less practical.

Observation  We describe 3 patients who were diagnosed as having delusional parasitosis that was successfully treated with a recently Food and Drug Administration–approved atypical antipsychotic agent, olanzapine (5 mg/d). Olanzapine has a more benign adverse effect profile than typical antipsychotic agents and eliminates the need for electrocardiographic monitoring. Olanzapine therapy has been associated with such adverse effects as sedation, hyperlipidemia, weight gain, and insulin resistance, all of which were infrequent in our patients.

Conclusion  Olanzapine is an atypical antipsychotic agent that can be used as a first-line agent in delusional parasitosis as a safer therapeutic option without a specialized monitoring regimen.


Author Affiliations: Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pa.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Pimozide at Least as Safe and Perhaps More Effective Than Olanzapine for Treatment of Morgellons Disease
Caroline S. Koblenzer
Arch Dermatol. 2006;142(10):1364.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Women's Dermatologic Diseases, Health Care Delivery, and Socioeconomic Barriers
June K. Robinson and Marcia Ramos-e-Siliva
Arch Dermatol. 2006;142(3):362-364.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Delusional Infestation, Including Delusions of Parasitosis: Results of Histologic Examination of Skin Biopsy and Patient-Provided Skin Specimens
Hylwa et al.
Arch Dermatol 2011;147:1041-1045.
ABSTRACT | FULL TEXT  

Self inflicted corneal abrasions due to delusional parasitosis
Meraj et al.
BMJ Case Reports 2011;2011:bcr0420114106-bcr0420114106.
ABSTRACT | FULL TEXT  

Delusional Infestation
Freudenmann and Lepping
Clin. Microbiol. Rev. 2009;22:690-732.
ABSTRACT | FULL TEXT  

Delusions of Parasitosis
Donabedian
Clinical Infectious Diseases 2007;45:e131-e134.
ABSTRACT | FULL TEXT  

Pimozide at least as safe and perhaps more effective than olanzapine for treatment of morgellons disease.
Koblenzer
Arch Dermatol 2006;142:1364-1364.
FULL TEXT  

Women's Dermatologic Diseases, Health Care Delivery, and Socioeconomic Barriers.
Robinson and Ramos-e-Siliva
Arch Dermatol 2006;142:362-364.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.